NVCT

19.3902.27%
JF

James F. Oliviero

Independent Director

Mr. James F. Oliviero, III, CFA had been the Chief Executive Officer and President of Checkpoint Therapeutics, Inc. since October 16, 2015 until May 30, 2025 and also had been its Director since October 15, 2018 until May 30, 2025. Mr. Oliviero has operational experience in the biotechnology industry. He served as the Chief Financial Officer of Keryx Biopharmaceuticals Inc. from April 2009 to October 2015. He served as a Treasurer of Keryx Biopharmaceuticals Inc. until October 2015 and also served as its Secretary. During his tenure at Keryx, Mr. Oliviero oversaw all finance, accounting, investor relations, corporate governance, business development and legal matters, as well as a leading member of the design of several clinical studies and the regulatory oversight of Keryx's new drug application for Auryxia, which successfully obtained FDA marketing approval in 2014 and also gained EMA marketing approval. From May 2003 to September 2015, Mr. Oliviero served in a variety of leadership capacities at Keryx Biopharmaceuticals, Inc. He served as Vice President of Finance at Keryx Biopharmaceuticals Inc. from March 2008 to April 2009. He served as Keryx's Controller from May 2003 to March 2008. From August 1999 to May 2003, Mr. Oliviero served as Director of Finance at ACCESS Oncology, Inc. From July 1997 to August 1999, he served as an Investment Banker at ING Barings Furman Selz in New York City, where he worked on various mergers and acquisitions and equity and debt transactions. He served as Director of Checkpoint Therapeutics, Inc. since October 16, 2015. He is a Director of Nuvectis Pharma Inc. since July 2021. He is a Chartered Financial Analyst charterholder. Mr. Oliviero has a B.B.A. in Finance with Highest Distinction from the Emory University's Goizueta Business School.

Positions